ロード中...
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
BACKGROUND: Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell carcinoma (RCC). Currently, there are no validated predictive biomarkers for sorafenib. Our purpose was to determine if sorafenib target expression is predictive of sorafenib sensitivity....
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3896780/ https://ncbi.nlm.nih.gov/pubmed/24423208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2867-14-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|